NeoStem, Inc. Advances Autoimmune Platform Through University of California, San Francisco (UCSF) Collaboration

Published: Jul 15, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, July 15, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced that the Company has executed agreements with the University of California, San Francisco and the laboratories of Jeffrey Bluestone, PhD, and Qizhi Tang, PhD, to collaborate on the development of human Regulatory T cells ("Tregs") for the treatment of type 1 diabetes ("T1D"), steroid resistant asthma, and organ transplant rejection. This collaboration advances NeoStem's role in the development and commercialization of immunomodulatory cellular therapeutic products for the treatment of intractable diseases involving the immune system.

Help employers find you! Check out all the jobs and post your resume.

Back to news